A 2026 animal study examined whether cannabidiolic acid (CBDA), the natural acidic precursor to CBD, could reduce brain inflammation caused by a high-fat diet. Rats fed a high-fat diet developed changes linked to neuroinflammation, including increased inflammatory lipid signaling and altered brain insulin pathways. CBDA treatment reduced arachidonic acid and several pro-inflammatory markers in the brain, including signals connected to cyclooxygenase activity and inflammatory cytokines.

CBDA also improved insulin signaling, particularly in the posterior cortex, and changed several markers associated with neurodegeneration. The study found lower expression of BACE1, a protein involved in amyloid production, along with increased levels of BDNF in cerebrospinal fluid, a protein important for nerve cell survival and function. Researchers also observed reduced markers of microglial activation, suggesting that CBDA may help calm inflammatory activity in the brain.

The authors concluded that CBDA showed anti-neuroinflammatory effects in this high-fat diet model and may help protect brain function by reducing inflammatory lipid signaling and improving insulin-related pathways. However, this was an animal study, not a human clinical trial, and the researchers specifically cautioned that more work is needed to establish long-term safety, dosing, and whether these effects translate to people.

Source: Konstantynowicz-Nowicka K, Opęchowska A, Domalewski M, et al. *The beneficial properties of CBDA in diet-induced neuroinflammation*. *Inflammopharmacology*. 2026;34(9):6213–6242. https://pmc.ncbi.nlm.nih.gov/articles/PMC13558366/